Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.91 USD | +2.36% | +9.83% | -26.92% |
04-09 | Harvard Bioscience Reducing Headcount | MT |
04-09 | Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-26.92% | 166M | D | ||
+7.30% | 219B | B | ||
+5.16% | 183B | B- | ||
+10.01% | 132B | B- | ||
+23.49% | 106B | A- | ||
-2.59% | 62.09B | A- | ||
+4.81% | 50.88B | B+ | ||
+11.11% | 50.8B | B+ | ||
-0.99% | 40.64B | A | ||
+24.79% | 31.59B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HBIO Stock
- Ratings Harvard Bioscience, Inc.